MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Summit Therapeutics PLC Company Profile (NASDAQ:SMMT)

Consensus Ratings for Summit Therapeutics PLC (NASDAQ:SMMT) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.33 (166.66% upside)

Analysts' Ratings History for Summit Therapeutics PLC (NASDAQ:SMMT)
Show:
DateFirmActionRatingPrice TargetActions
6/21/2016Janney Montgomery ScottInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/2/2015Needham & Company LLCReiterated RatingBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2015JMP SecuritiesInitiated CoverageOutperform$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Summit Therapeutics PLC (NASDAQ:SMMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/27/2015Q215($0.06)($0.55)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/11/2015Q115($0.06)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Summit Therapeutics PLC (NASDAQ:SMMT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.78)($0.78)($0.78)
Q3 20171($0.64)($0.64)($0.64)
Q4 20171($0.71)($0.71)($0.71)
(Data provided by Zacks Investment Research)
Dividend History for Summit Therapeutics PLC (NASDAQ:SMMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Summit Therapeutics PLC (NASDAQ:SMMT)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Summit Therapeutics PLC (NASDAQ:SMMT)
DateHeadline
06/24/16 09:00 AMSummit Therapeutics plc : Award of Options
06/23/16 07:08 PMSummit Therapeutics PLC (NASDAQ:SMMT) price target held steady to $0 as issued in a report today by Janney Capital - Breaking Finance News
06/22/16 06:25 PMSummit uses more than gut instinct to prove C.diff antibiotic's worth
06/22/16 06:25 PMSummit Therapeutics PLC (NASDAQ:SMMT) price target held steady to $0 as issued in a report today by Janney Capital
06/21/16 01:40 PMSummit Therapeutics PLC (ADR) (SMMT) Is Hot On Sarepta Therapeutics Inc (SRPT)’s DMD Tail -
06/21/16 10:46 AMSummit Therapeutics PLC (ADR) (NASDAQ:SMMT) Is Hot On Sarepta Therapeutics Inc (NASDAQ:SRPT)'s DMD Tail - Market Exclusive
06/20/16 11:49 AMSummit’s Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection - [at noodls] - Summit Corporation plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT'S RIDINILAZOLE PRESERVES MICROBIOME DURING TREATMENT OF DIFFICILE INFECTION Microbiome-Sparing Action ...
06/18/16 05:35 PMSummit Therapeutics : First Patient Enrolled in Summits PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD
06/18/16 10:32 AMAyretrade, Inc. (SUMM) Announces Enrollment of First Patient in PhaseOut DMD
06/17/16 06:11 PMSummit Therapeutics plc : Notice of AGM
06/17/16 09:07 AMSummit Therapeutics recruits first DMD phase II trial patient
06/17/16 07:19 AMFirst Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys with DMD - [at noodls] - 7e88d7fb-3ed3-48cd-ac6e-24bef220f55c.pdf Summit Therapeutics plc ("Summit" or "the Company") FIRST PATIENT ENROLLED IN SUMMIT'S PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN ...
06/16/16 07:39 AMSummit to Present at JMP Securities Life Sciences Conference - [at noodls] - f2d91ddf-358f-4c6d-9111-841417a3ad7d.pdf Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT JMP SECURITIES LIFE SCIENCES CONFERENCE Oxford, UK, 16 ...
06/13/16 09:26 AMSmall British Companies Are Less Wary of an Exit From EU
06/08/16 09:33 AMSummit Therapeutics to host New York DMD event
06/08/16 09:18 AMSummit Therapeutics to Host Utrophin R&D Day 15 June 2016 - [at noodls] - d9fc8eaf-b157-4dac-87a8-292d9f74dd81.pdf Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO HOST UTROPHIN R&D DAY 15 JUNE 2016 Oxford, UK, 8 June 2016 - Summit ...
06/07/16 09:15 AMSarepta surges on new hopes for its DMD drug
06/03/16 09:27 AMSummit Therapeutics Plc (SMMT) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News
06/02/16 06:57 PMSummit set to start dosing in DMD trial in second quarter - Proactive Investors USA & Canada - Proactive Investors USA & CanadaSummit set to start dosing in DMD trial in second quarterProactive Investors USA & CanadaMuscle data from a Phase 2 clinical trial for its Duchenne muscular dystrophy (DMD) treatment Ezutromid is expected in January 2017, drug developer Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM) revealed today. It expects to start enrolling and ...Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational ProgressGlobeNewswire (press release)all 2 news articles »
06/02/16 12:55 PMFinancial Results from the First Quarter Ended 30 April 2016 - [at noodls] - Summit Corporation plc Summit Therapeutics plc‌‌‌‌‌‌ ("Summit" or the "Company") SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2016 AND OPERATIONAL ...
06/02/16 09:39 AMSummit Therapeutics plc : 1st Quarter Results - Oxford, UK, 2 June 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and C. difficile infection ('CDI'), today reports its financial results for ...
06/02/16 09:39 AMSummit set to start dosing in DMD trial in second quarter - Muscle data from a Phase 2 clinical trial for its Duchenne muscular dystrophy (DMD) treatment Ezutromid is expected in January 2017, drug developer Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM) revealed today. It expects to start enrolling and dosing ...
06/02/16 06:00 AMSummit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress - [GlobeNewswire] - OXFORD, United Kingdom, June 02, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, today reports ...
06/01/16 10:43 AMSummit Therapeutics Plc :SMMT-US: Earnings Analysis: Q4, 2016 By the Numbers : June 1, 2016 -
06/01/16 09:26 AMSummit Therapeutics plc (NASDAQ:SMMT) To Release Earnings On Thursday - Share Trading News - Summit Therapeutics plc (NASDAQ:SMMT) To Release Earnings On ThursdayShare Trading NewsThese holdings make up 5.27% of the company's outstanding shares. The stock increased 2.63% or $0.22 during the last trading session, hitting $8.65. Summit Therapeutics plc (NASDAQ:SMMT) has fallen 17.8% over the past 6 months and is downtrending.
05/31/16 06:00 AMSummit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016 - [GlobeNewswire] - OXFORD, United Kingdom, May 31, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting ...
05/30/16 09:03 PMNext Weeks Broker Price Targets For Summit Therapeutics Plc (SMMT) - Share Trading News - Next Weeks Broker Price Targets For Summit Therapeutics Plc (SMMT)Share Trading NewsSummit Therapeutics plc has a 50 day moving average of 8.20 and a 200 day moving average of 8.67. The stock's market capitalization is 103.02M, it has a 52-week low of 4.26 and a 52-week high of 13.30. The share price of the company (SMMT) was up ...and more »
05/26/16 12:43 PMSummit Therapeutics to present CDI antibiotic results - Drug discovery and development company Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) will present positive phase II trial data on its Clostridium difficile infection (CDI) drug at the ASM Microbe 2016 meeting in Boston next month. The group’s ...
05/23/16 08:16 AMSummit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole’s Preservation of the Microbiome in CDI Patients at ASM Microbe 2016 - [at noodls] - Summit Corporation plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT TO PRESENT PHASE 2 CoDIFy TRIAL DATA HIGHLIGHTING RIDINILAZOLE'S PRESERVATION OF THE MICROBIOME IN ...
05/23/16 06:00 AMSummit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM Microbe 2016 - [GlobeNewswire] - OXFORD, United Kingdom, May 23, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces ...
05/10/16 11:47 AMLosses widen at Summit Therapeutics -
05/10/16 06:18 AMFinancial Results for Fourth Quarter and Fiscal Year Ended 31 January 2016 - [at noodls] - Summit Corporation plc Summit Therapeutics plc‌‌‌‌‌‌ ("Summit" or the "Company") SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED 31 JANUARY ...
05/10/16 06:00 AMSummit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016 - [GlobeNewswire] - OXFORD, United Kingdom, May 10, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, today reports ...
05/06/16 06:00 AMSummit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016 - [GlobeNewswire] - OXFORD, United Kingdom, May 06, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will ...
04/28/16 06:10 AMFurther US Patent Granted for CDI Antibiotic Ridinilazole - [at noodls] - Summit Corporation plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT ANNOUNCES FURTHER US PATENT GRANTED FOR CDI ANTIBIOTIC RIDINILAZOLE Oxford, UK, 28 April 2016 - Summit ...
04/28/16 06:00 AMSummit Announces Further US Patent Granted for CDI Antibiotic Ridinilazole - [GlobeNewswire] - OXFORD, United Kingdom, April 28, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces ...
04/26/16 10:35 AMOn the heels of bad news for Duchenne comes good news for Summit -
04/26/16 09:44 AMSummit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid - [at noodls] - 8620a22b-a59f-4993-9a4d-1b310c61c84c.pdf Summit Therapeutics plc ("Summit" or "the Company") SUMMIT'S IND CLEARED BY FDA ALLOWING EXPANSION OF PhaseOut DMD, A PHASE 2 CLINICAL TRIAL ...
04/26/16 06:00 AMSummit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US - [GlobeNewswire] - Enrolment of Patients with DMD in the US Expected to Start 3 Q 2016 Utrophin Modulation Offers Differentiated Approach in DMD OXFORD, United Kingdom, April 26, 2016-- Summit Therapeutics plc, the drug ...
04/11/16 07:20 AMPositive Results from Phase 2 CoDIFy Trial Presented at ECCMID - [at noodls] - 2c0b9a96-df97-4a0c-8d1e-9882ff0f124b.pdf Summit Therapeutics plc ("Summit" or "the Company") POSITIVE RESULTS FROM SUMMIT'S PHASE 2 CoDIFy TRIAL HIGHLIGHT POTENTIAL OF RIDINILAZOLE ...
04/11/16 06:00 AMPositive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infection - [GlobeNewswire] - OXFORD, United Kingdom, April 11, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces ...
02/24/16 09:23 AMSummit Therapeutics hails strong C-difficile findings -
02/18/16 01:55 PMSummit Therapeutics To Participate In SunTrust Robinson Humphrey's 2016 Orphan Drug Day - OXFORD, United Kingdom, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that ...
02/17/16 06:00 AMSummit Therapeutics to Participate in SunTrust Robinson Humphrey’s 2016 Orphan Drug Day - [GlobeNewswire] - OXFORD, United Kingdom, Feb. 17, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces ...
02/03/16 01:53 PMSummit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference - EIN News (press release) - Summit Therapeutics to Present at 18th Annual BIO CEO & Investor ConferenceEIN News (press release)03, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn ...Summit Therapeutics to Present at BIO CEO & Investor ConferencePharmiWeb.com (press release)all 2 news articles »
02/02/16 01:19 PMCanaccord Genuity Initiates Coverage on Summit Therapeutics PLC (ADR) to Buy - WallStreet Prudent - Canaccord Genuity Initiates Coverage on Summit Therapeutics PLC (ADR) to BuyWallStreet PrudentCanaccord Genuity Initiates Coverage on Summit Therapeutics PLC (ADR)(NASDAQ:SMMT). The shares have been rated Buy. The rating by Canaccord Genuity was issued on Feb 1, 2016. Summit Therapeutics PLC (ADR)(SMMT) last announced its ...and more »
01/23/16 01:00 PMSummit Therapeutics plc (SMMT) - Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a ...
01/22/16 01:34 PMAyretrade, Inc. (SUMM) Announces Receipt of Regulatory Approval to Commence PhaseOut DMD - StreetInsider.com - Ayretrade, Inc. (SUMM) Announces Receipt of Regulatory Approval to Commence PhaseOut DMDStreetInsider.comSummit Therapeutics plc (NASDAQ: SMMT) announces that it has received approval from the UK Medicines and Healthcare products Regulatory Agency and the Research Ethics Committee to initiate PhaseOut DMD, a Phase 2 proof of concept clinical trial of ...
01/21/16 01:36 PMSummit Therapeutics Receives Phase 2 Trial Approval for DMD Patients - Business Finance News - Business Finance NewsSummit Therapeutics Receives Phase 2 Trial Approval for DMD PatientsBusiness Finance NewsSummit Therapeutics PLC (NASDAQ:SMMT) has obtained the approval for the phase 2 proof of concept trial of SMT C1100 candidate, from the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the Research Ethics Committees (RECs).Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a ...GlobeNewswire (press release)all 18 news articles »
01/19/16 06:03 AM7:03 am Summit Therapeutics announces that the European Patent Office has granted a key patent covering the novel antibiotic, ridinilazole; opposition period has expired with the patent having faced no challenge -
About Summit Therapeutics PLC

Summit Therapeutics PLC logoSummit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The Company's lead DMD product candidate is SMT C1100, an orally administered small molecule. The Company's lead CDI product candidate is SMT19969, an orally administered small molecule antibiotic. The Company subsidiaries include Summit Therapeutics, Inc., Summit (Oxford) Limited, Summit (Wales) Limited and MuOx Limited, among others.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SMMT
  • CUSIP:
Key Metrics:
  • Previous Close: $8.00
  • 50 Day Moving Average: $8.3428
  • 200 Day Moving Average: $8.4424
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $98.11M
  • Current Quarter EPS Consensus Estimate: $-0.5900 EPS
Additional Links:
Summit Therapeutics PLC (NASDAQ:SMMT) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha